Hub : Traits :

Crohns Disease (2017)

1366 significantly associated models · 266 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 7314655 8738937 2 1 2.3e-08 7.4e-08 3.8e-06 26 PARK7
2 1 66304567 68152438 4 5 1.6e-69 5.8e-97 9.0e-25 76 IL23R MIER1
3 1 113751640 115152814 1 1 1.1e-08 6.4e-16 1.6e-09 44 DCLRE1B
4 1 154325302 156572984 16 1 2.5e-11 6.8e-09 4.0e-01 98 ADAM15
5 1 160559549 161098128 2 1 1.7e-07 3.7e-08 3.7e-03 72 ITLN1
6 2 24324172 25837917 3 1 1.0e-13 2.6e-11 8.8e-01 100 ADCY3
7 2 26883355 29344127 3 2 5.2e-12 6.3e-11 9.7e-01 100 AC074117.10 RP11-373D23.3
8 2 42753863 44157441 2 1 4.0e-09 1.5e-11 9.2e-05 66 AC010883.5
9 2 60466491 62107632 5 1 7.2e-13 5.9e-14 1.5e-02 90 PEX13
10 2 101981794 103767612 4 2 7.3e-13 1.6e-13 1.0e+00 100 IL18R1 IL1RL1
11 2 197976089 200117777 1 1 5.9e-08 5.0e-08 1.5e-01 93 PLCL1
12 2 230396934 231875433 1 1 8.6e-08 2.8e-14 2.5e-08 46 SP140
13 2 233227833 235170697 5 2 5.4e-61 1.8e-62 1.0e+00 100 ATG16L1 SCARNA5
14 3 47911521 50921261 29 1 4.9e-26 4.6e-24 3.4e-02 96 MST1
15 3 52242902 53860103 2 1 4.6e-09 7.9e-09 3.0e-01 97 RFT1
16 3 140350567 141867638 1 1 1.1e-07 3.1e-08 1.0e+00 100 ZBTB38
17 4 122377715 123976639 1 1 3.6e-08 2.4e-08 1.7e-01 94 KIAA1109
18 5 39986432 41555158 4 3 1.2e-20 8.3e-56 2.8e-28 51 CARD6 PRKAA1 PTGER4
19 5 95519506 97065386 3 1 4.7e-15 5.1e-15 1.0e+00 100 ERAP2
20 5 129797129 132900729 17 6 1.1e-33 5.6e-36 NaN NaN HINT1 PDLIM4 SLC22A5
21 5 140789933 142230251 1 1 1.5e-12 4.1e-12 3.4e-01 98 NDFIP1
22 5 149577574 151236214 6 1 1.3e-21 2.1e-20 3.9e-02 95 DCTN4
23 5 158501850 159005439 1 1 1.2e-18 7.5e-22 1.2e-04 84 IL12B
24 6 127196109 127764305 1 1 2.7e-07 1.8e-09 1.4e-03 72 RSPO3
25 6 166651581 167841508 4 1 4.5e-23 3.7e-22 3.1e-02 95 RNASET2
26 7 99591418 100979310 1 1 4.6e-08 5.0e-06 8.4e-02 86 GIGYF1
27 9 108998 1162143 1 1 2.9e-07 6.0e-07 6.6e-01 99 DOCK8
28 9 4287179 5824205 2 1 3.7e-14 1.6e-16 1.0e-03 84 IGHEP2
29 9 116849447 118389134 2 2 4.3e-21 1.8e-21 4.6e-02 96 TNFSF15 TNFSF8
30 9 138525778 140321666 10 3 1.2e-28 3.1e-30 1.0e+00 100 CARD9 RP11-611D20.2
31 10 30028267 31432776 1 1 4.1e-08 1.9e-11 2.2e-05 60 MAP3K8
32 10 34607015 36198981 2 1 8.6e-15 6.3e-15 1.0e+00 100 CUL2
33 10 63856856 65264300 3 1 1.7e-17 5.5e-29 3.9e-14 54 ADO
34 10 74714177 76323150 13 1 1.8e-11 6.0e-11 3.4e-03 80 RP11-464F9.22
35 10 80130592 82984432 2 2 5.3e-15 8.9e-15 3.0e-05 71 TSPAN14 ZMIZ1
36 11 63316786 64820283 2 1 1.9e-08 3.2e-07 2.2e-01 94 PPP1R14B
37 11 64954053 66333072 1 1 2.0e-07 2.0e-06 1.0e-02 71 FIBP
38 11 75457950 77069746 2 2 1.1e-13 4.7e-24 1.9e-10 60 C11orf30 LRRC32
39 12 39904158 41454590 1 2 2.8e-11 6.1e-21 3.6e-09 60 LRRK2
40 13 43756650 45157394 1 1 3.3e-12 1.4e-13 1.0e+00 100 LACC1
41 14 87606646 89154624 2 3 7.6e-10 2.0e-12 3.5e-01 98 GALC GPR65
42 15 66662107 68183665 1 2 1.2e-14 2.4e-19 8.1e-05 81 SMAD3
43 16 10646170 12426645 2 1 8.4e-11 2.8e-08 9.1e-02 91 RMI2
44 16 27655848 30141258 24 1 9.6e-15 6.9e-13 2.8e-01 98 NFATC2IP
45 16 49403920 51535063 8 11 3.3e-78 1.8e-108 NaN NaN ADCY7 BRD7 CYLD HEATR3 NKD1 NOD2 RP11-429P3.3
46 17 25295032 26643541 1 1 4.3e-08 1.5e-09 5.2e-03 79 KSR1
47 17 36710513 39048774 15 1 3.7e-19 5.1e-19 1.3e-02 92 PNMT
48 17 39328012 41699963 7 2 3.8e-12 1.8e-12 2.0e-02 89 NAGLU PTRF
49 18 12538482 13133577 1 1 8.1e-21 1.4e-17 9.6e-01 100 PTPN2
50 19 388413 1802433 3 8 5.1e-16 9.1e-21 NaN NaN GPX4 POLR2E
51 19 9829303 11376675 3 2 3.7e-10 2.8e-13 9.4e-11 21 CDKN2D PDE4A
52 19 46157004 47589895 1 1 4.6e-08 3.6e-07 1.0e+00 100 PPP5C
53 19 48464978 49935001 3 1 1.6e-11 2.3e-11 1.0e+00 100 FUT2
54 19 58389355 59095126 1 1 1.4e-07 4.6e-06 4.7e-02 81 RPL23AP79
55 20 43825556 45456440 3 2 3.7e-09 1.3e-09 3.0e-02 87 CD40 MMP9
56 20 61522825 62912463 11 1 2.9e-15 2.7e-13 3.7e-03 84 STMN3
57 21 15634304 17135372 1 1 1.3e-08 2.7e-27 2.2e-20 27 NRIP1
58 21 34077531 35561665 2 2 2.4e-07 1.1e-14 1.8e-03 84 DNAJC28 IFNGR2
59 21 44948764 46443886 2 1 3.2e-14 2.0e-19 2.2e-07 67 ICOSLG
60 22 21075537 22685340 5 1 3.4e-16 6.3e-16 1.0e+00 100 CCDC116
61 22 29585080 31118395 1 1 2.7e-08 4.2e-07 1.9e-01 93 MTMR3
62 22 36500899 37910395 2 1 4.9e-10 1.8e-08 4.9e-01 98 NCF4
63 22 38719189 40529415 3 2 1.1e-15 7.7e-21 8.8e-09 62 APOBEC3D SYNGR1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 1.18 3 0 0.0 0.00 1.0e+00 CD40 FUT2 GIGYF1
Depressed Affect (Nagel 2018) 1.18 2 1 2.2 0.00 1.0e+00 CD40 MST1
Intelligence (Savage-Jansen 2018) 1.19 2 2 4.4 0.00 1.0e+00 MST1 NFATC2IP
Neuroticism (Nagel 2018) 1.15 2 1 2.2 0.00 1.0e+00 CD40 RNASET2
Schizophrenia (2018) 1.14 1 0 0.0 0.00 1.0e+00 GIGYF1
Worry (Nagel 2018) 1.20 2 0 0.0 0.00 1.0e+00 CD40 MTMR3
Irritable Bowel Disease (IBD) 20.38 73 59 131.1 0.98 8.2e-65 AC010883.5 AC074117.10 ADAM15 ADCY3 ADCY7 ADO APOBEC3D ATG16L1 BRD7 C11orf30 CARD9 CCDC116 CD40 CDKN2D CUL2 CYLD DCTN4 DOCK8 ERAP2 FIBP FUT2 GALC GIGYF1 GPR65 GPX4 HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 IL23R ITLN1 KIAA1109 LACC1 LRRC32 LRRK2 MAP3K8 MIER1 MMP9 MST1 MTMR3 NAGLU NDFIP1 NFATC2IP NKD1 NOD2 NRIP1 PARK7 PDE4A PDLIM4 PEX13 PNMT POLR2E PPP1R14B PPP5C PTGER4 PTPN2 PTRF RMI2 RNASET2 RP11-373D23.3 RP11-464F9.22 RP11-611D20.2 RPL23AP79 SCARNA5 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 TSPAN14 ZMIZ1
Ulcerative Colitis (UC) 7.51 26 13 28.9 0.94 6.3e-14 ADO C11orf30 CARD9 CCDC116 ICOSLG IGHEP2 IL12B IL23R KIAA1109 LRRC32 MST1 MTMR3 NAGLU NFATC2IP NRIP1 PARK7 PEX13 PNMT PTPN2 PTRF RP11-611D20.2 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15
Reaction Time 0.88 1 0 0.0 0.00 1.0e+00 ADCY3
Verbal and Numeric Reasoning (VNR) 1.07 3 2 4.4 0.00 1.0e+00 ADCY3 MST1 NFATC2IP
Breast Cancer 1.73 5 4 8.9 -0.25 6.3e-01 ADCY3 DCLRE1B PARK7 SLC22A5 ZBTB38
Prostate Cancer 1.39 1 1 2.2 0.00 1.0e+00 C11orf30
Age at First Birth 1.01 1 0 0.0 0.00 1.0e+00 MST1
Body Mass Index (BMI) (2010) 1.41 2 2 4.4 0.00 1.0e+00 ADCY3 NFATC2IP
Crohns Disease (2012) 21.34 59 37 82.2 0.99 1.2e-64 ADAM15 ADCY3 ADCY7 ADO ATG16L1 BRD7 CARD6 CCDC116 CUL2 CYLD DCTN4 ERAP2 FUT2 GALC HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 IL23R LACC1 LRRC32 LRRK2 MIER1 MST1 MTMR3 NAGLU NCF4 NDFIP1 NFATC2IP NKD1 NOD2 PDE4A PDLIM4 PEX13 PLCL1 PNMT PPP1R14B PRKAA1 PTGER4 PTPN2 PTRF RFT1 RMI2 RNASET2 RP11-373D23.3 RP11-464F9.22 RPL23AP79 RSPO3 SCARNA5 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 TNFSF8 TSPAN14 ZMIZ1
Fasting Glucose 1.94 2 1 2.2 0.00 1.0e+00 AC074117.10 RP11-373D23.3
HDL Cholesterol 1.51 2 2 4.4 0.00 1.0e+00 CCDC116 PNMT
LDL Cholesterol 0.99 1 1 2.2 0.00 1.0e+00 FUT2
Lupus 2.00 2 1 2.2 0.00 1.0e+00 CCDC116 DCLRE1B
Primary Biliary Cirrhosis 2.13 4 3 6.7 1.00 1.8e-03 PNMT PPP1R14B RMI2 SYNGR1
Rheumatoid Arthritis 3.51 4 3 6.7 -0.60 4.0e-01 CD40 DCLRE1B PNMT PTPN2
Schizophrenia (2014) 1.11 3 0 0.0 0.00 1.0e+00 GIGYF1 LACC1 PLCL1
Triglycerides 3.99 3 2 4.4 0.00 1.0e+00 AC074117.10 MMP9 RP11-373D23.3
Ulcerative Colitis 6.45 17 8 17.8 0.94 8.7e-09 BRD7 CARD9 CUL2 ICOSLG IGHEP2 IL12B IL23R LRRK2 MST1 PARK7 PEX13 PNMT PTRF SLC22A5 STMN3 SYNGR1 TNFSF15
Blood Eosinophil Count 6.07 28 22 48.9 -0.09 6.3e-01 AC010883.5 ADCY3 ADO C11orf30 CARD9 CCDC116 CUL2 ERAP2 GIGYF1 GPR65 GPX4 HINT1 IGHEP2 IL1RL1 KIAA1109 LRRC32 NCF4 NDFIP1 PDLIM4 POLR2E PPP5C PTPN2 RFT1 SLC22A5 SMAD3 SP140 TNFSF15 TNFSF8
Blood Platelet Count 2.15 27 17 37.8 -0.23 2.1e-01 AC010883.5 AC074117.10 ADO ATG16L1 C11orf30 DOCK8 FUT2 HEATR3 HINT1 IGHEP2 MST1 MTMR3 NDFIP1 PDLIM4 PNMT POLR2E PPP1R14B PTGER4 RMI2 RP11-373D23.3 RP11-429P3.3 RP11-464F9.22 RPL23AP79 RSPO3 SLC22A5 STMN3 ZMIZ1
Blood Red Count 1.39 17 11 24.4 0.28 2.4e-01 DOCK8 GIGYF1 GPX4 IGHEP2 MST1 NDFIP1 NFATC2IP PLCL1 PNMT POLR2E PPP5C PTGER4 PTPN2 RP11-373D23.3 RSPO3 STMN3 ZBTB38
Blood White Count 3.60 24 18 40.0 -0.03 8.9e-01 AC074117.10 ADCY3 ADO CARD9 CCDC116 CDKN2D DCLRE1B ERAP2 GPX4 HEATR3 HINT1 NDFIP1 PDE4A PDLIM4 PEX13 PNMT POLR2E RFT1 RNASET2 RP11-373D23.3 RP11-429P3.3 SLC22A5 STMN3 TSPAN14
Heel T-Score 2.14 13 7 15.6 -0.17 5.9e-01 AC010883.5 CCDC116 DOCK8 MMP9 MST1 POLR2E PPP1R14B RFT1 RPL23AP79 RSPO3 SLC22A5 TSPAN14 ZBTB38
BMI 1.57 10 6 13.3 0.54 1.1e-01 ADCY3 FIBP GALC GPR65 HINT1 MST1 NFATC2IP PLCL1 PPP1R14B RFT1
Height 2.92 25 21 46.7 0.34 5.8e-02 AC010883.5 AC074117.10 ADCY3 ADO APOBEC3D ATG16L1 C11orf30 CARD9 CCDC116 FUT2 GPX4 HINT1 IL18R1 IL23R MIER1 MTMR3 PARK7 PDE4A PDLIM4 POLR2E PTRF RFT1 RP11-373D23.3 SLC22A5 ZBTB38
Waist Hip Ratio (WHR) 1.12 5 1 2.2 0.56 3.3e-01 AC010883.5 FUT2 PPP1R14B RSPO3 ZBTB38
Systolic Blood Pressure 1.20 14 6 13.3 0.14 6.2e-01 AC074117.10 ADCY3 ADO C11orf30 CCDC116 CUL2 DOCK8 ERAP2 FUT2 PRKAA1 RP11-464F9.22 SMAD3 STMN3 TSPAN14
Smoking Status 1.02 1 0 0.0 0.00 1.0e+00 PPP1R14B
Allergy or Eczema 5.11 18 13 28.9 0.72 5.0e-04 AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 KIAA1109 LRRC32 NAGLU NDFIP1 NFATC2IP PEX13 PLCL1 PNMT PTGER4 RP11-373D23.3 SMAD3 STMN3 ZBTB38
Cardiovascular Disease 1.58 7 3 6.7 0.63 1.3e-01 AC074117.10 ADO ATG16L1 FUT2 NFATC2IP SLC22A5 STMN3
Hypothyroidism (self reported) 3.98 12 6 13.3 0.00 9.9e-01 BRD7 DCLRE1B DNAJC28 FUT2 GIGYF1 MTMR3 NRIP1 PPP1R14B PTPN2 PTRF RNASET2 ZMIZ1
Respiratory disease 5.52 9 7 15.6 0.17 5.8e-01 KIAA1109 LACC1 LRRC32 NCF4 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Type 2 Diabetes (T2D) (2018) 1.86 3 2 4.4 0.00 1.0e+00 AC010883.5 AC074117.10 STMN3
Lung FEV1/FVC ratio 1.80 11 6 13.3 0.41 1.3e-01 AC010883.5 ADCY3 ADO FUT2 IL18R1 PNMT RP11-464F9.22 SLC22A5 SMAD3 TSPAN14 ZBTB38
Lung FVC 1.33 10 7 15.6 -0.76 4.4e-03 CARD9 HINT1 NFATC2IP PARK7 PDLIM4 PNMT RP11-464F9.22 SLC22A5 STMN3 ZBTB38
Neuroticism 1.07 1 1 2.2 0.00 1.0e+00 CD40
Chronotype (morning person) 1.04 2 0 0.0 0.00 1.0e+00 MMP9 PLCL1
Hair Pigment 0.44 9 8 17.8 0.56 1.1e-01 AC010883.5 AC074117.10 ADAM15 ADCY3 CUL2 DOCK8 GIGYF1 SYNGR1 ZBTB38
Tanning 0.28 4 3 6.7 -0.97 3.4e-02 AC074117.10 ADCY3 ADO IL18R1
Hand grip strength (left) 1.78 6 5 11.1 0.71 4.9e-02 ADCY3 HINT1 PDLIM4 RFT1 SLC22A5 ZBTB38
Number of treatments/medications taken 1.53 2 0 0.0 0.00 1.0e+00 AC074117.10 DCLRE1B
Average weekly spirits intake 1.26 2 0 0.0 0.00 1.0e+00 FUT2 MST1
Relative age of first facial hair 1.11 2 0 0.0 0.00 1.0e+00 CUL2 ZBTB38
Systolic blood pressure, automated reading 1.09 1 1 2.2 0.00 1.0e+00 ADO
Medication: Metformin 1.73 2 1 2.2 0.00 1.0e+00 AC010883.5 AC074117.10
Diabetes (father) 1.73 1 1 2.2 0.00 1.0e+00 AC010883.5
Impedance of leg (right) 1.08 9 5 11.1 0.00 1.0e+00 AC010883.5 AC074117.10 ADCY3 CCDC116 HEATR3 HINT1 NFATC2IP PLCL1 RP11-429P3.3
Leg fat-free mass (left) 2.12 10 7 15.6 0.61 3.7e-02 AC074117.10 ADO HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38 ZMIZ1
Trunk fat percentage 1.52 4 4 8.9 0.57 4.3e-01 ADCY3 MST1 NFATC2IP ZBTB38
Hand grip strength (right) 1.85 7 6 13.3 0.47 1.7e-01 ADCY3 HINT1 NFATC2IP PDLIM4 RFT1 SLC22A5 ZBTB38
Current tobacco smoking 1.18 1 1 2.2 0.00 1.0e+00 STMN3
Fed-up feelings 1.40 2 1 2.2 0.00 1.0e+00 MST1 PPP1R14B
Taking other prescription medications 1.72 3 0 0.0 0.00 1.0e+00 DCLRE1B PPP1R14B RNASET2
Age when periods started (menarche) 1.25 3 1 2.2 0.00 1.0e+00 ADCY3 C11orf30 FUT2
Heel bone mineral density (BMD) T-score, automated (left) 1.89 2 1 2.2 0.00 1.0e+00 MST1 RSPO3
High blood pressure 1.36 4 2 4.4 0.25 6.8e-01 ADO FUT2 PDLIM4 SLC22A5
Hayfever, allergic rhinitis or eczema 5.06 18 12 26.7 0.62 3.6e-03 AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 KIAA1109 LRRC32 NAGLU NDFIP1 PEX13 PLCL1 PNMT PTGER4 RP11-373D23.3 SLC22A5 SMAD3 STMN3 ZBTB38
Medication: Levothyroxine sodium 3.10 6 2 4.4 -0.13 8.0e-01 BRD7 DCLRE1B GIGYF1 PTPN2 PTRF RNASET2
Sitting height 2.39 16 10 22.2 0.30 2.3e-01 AC074117.10 ADCY3 ADO CARD9 CCDC116 DCTN4 FUT2 GPX4 HINT1 MIER1 MTMR3 PDLIM4 PPP1R14B RFT1 SLC22A5 ZBTB38
Body mass index (BMI) 1.41 6 3 6.7 0.55 2.6e-01 ADCY3 GALC MST1 NFATC2IP PLCL1 RFT1
Impedance of leg (left) 1.13 10 5 11.1 -0.10 7.8e-01 AC010883.5 AC074117.10 ADCY3 CCDC116 FIBP HEATR3 HINT1 NFATC2IP PLCL1 RP11-429P3.3
Leg predicted mass (left) 2.12 10 7 15.6 0.66 1.9e-02 AC074117.10 ADO HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 PPP1R14B SLC22A5 ZBTB38
Trunk fat mass 1.67 5 5 11.1 0.58 3.1e-01 ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Waist circumference 1.47 6 3 6.7 0.77 7.1e-02 ADCY3 HINT1 NFATC2IP RSPO3 ZBTB38 ZMIZ1
Nervous feelings 0.97 1 0 0.0 0.00 1.0e+00 MTMR3
Had menopause 1.24 1 1 2.2 0.00 1.0e+00 AC074117.10
Forced vital capacity (FVC) 1.24 6 4 8.9 0.24 6.4e-01 ADCY3 MMP9 MTMR3 RFT1 STMN3 ZBTB38
Heel bone mineral density (BMD) T-score, automated (right) 1.83 3 1 2.2 0.00 1.0e+00 MST1 RSPO3 ZBTB38
Qualifications: None of the above 0.89 3 1 2.2 0.00 1.0e+00 MST1 NFATC2IP RFT1
Mouth/teeth dental problems 1.23 1 0 0.0 0.00 1.0e+00 FUT2
Allergy 5.71 17 10 22.2 -0.38 9.0e-02 C11orf30 CCDC116 HINT1 IGHEP2 KIAA1109 LRRC32 NCF4 NDFIP1 PDLIM4 PEX13 PLCL1 PNMT RP11-373D23.3 SLC22A5 SMAD3 STMN3 ZBTB38
Diabetes (self-reported) 1.87 2 1 2.2 0.00 1.0e+00 AC010883.5 AC074117.10
Hayfever/allergic rhinitis (self-reported) 3.25 6 3 6.7 0.70 7.9e-02 C11orf30 KIAA1109 LRRC32 PLCL1 PNMT SMAD3
Medication: Simvastatin 1.44 2 1 2.2 0.00 1.0e+00 AC074117.10 FUT2
Fluid intelligence score 1.11 2 1 2.2 0.00 1.0e+00 MST1 NFATC2IP
Neuroticism score 1.10 2 0 0.0 0.00 1.0e+00 AC010883.5 CD40
Weight 1.87 10 6 13.3 0.53 7.4e-02 AC074117.10 ADCY3 HINT1 MST1 NFATC2IP PDE4A PDLIM4 PPP1R14B SLC22A5 ZBTB38
Impedance of arm (right) 1.14 6 4 8.9 0.88 2.0e-02 AC074117.10 LRRC32 PLCL1 RFT1 RP11-373D23.3 SMAD3
Arm fat percentage (right) 1.65 4 3 6.7 0.60 4.0e-01 ADCY3 GALC MST1 NFATC2IP
Trunk fat-free mass 2.17 14 10 22.2 0.52 4.0e-02 AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Hip circumference 1.58 6 4 8.9 0.75 8.7e-02 ADCY3 HINT1 NFATC2IP PDE4A PPP1R14B ZBTB38
Alcohol intake versus 10 years previously 1.46 3 1 2.2 0.00 1.0e+00 AC074117.10 FUT2 MST1
Frequency of tiredness / lethargy in last 2 weeks 1.34 1 0 0.0 0.00 1.0e+00 RP11-464F9.22
Forced expiratory volume in 1-second (FEV1) 1.27 6 3 6.7 0.56 1.5e-01 ADCY3 MTMR3 RFT1 SLC22A5 STMN3 ZBTB38
Pulse rate 1.63 3 2 4.4 0.00 1.0e+00 AC074117.10 GIGYF1 ZBTB38
Qualifications: A levels/AS levels or equivalent 1.12 1 1 2.2 0.00 1.0e+00 MST1
Mouth/teeth dental problems: Dentures 1.33 3 1 2.2 0.00 1.0e+00 ADCY3 FUT2 PNMT
Asthma 5.63 9 7 15.6 0.18 5.7e-01 CUL2 KIAA1109 LACC1 LRRC32 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Medication: Cholesterol lowering 1.55 2 2 4.4 0.00 1.0e+00 AC074117.10 FUT2
Forced expiratory volume in 1-second (FEV1), Best measure 1.30 8 2 4.4 0.64 4.5e-02 ADCY3 ADO ICOSLG MTMR3 RFT1 SLC22A5 STMN3 ZBTB38
Impedance of arm (left) 1.11 5 3 6.7 0.89 4.5e-02 AC074117.10 LRRC32 PLCL1 RP11-373D23.3 SMAD3
Arm fat mass (right) 1.61 6 5 11.1 0.61 2.0e-01 ADCY3 GALC HINT1 MST1 NFATC2IP ZBTB38
Trunk predicted mass 2.18 14 10 22.2 0.52 4.1e-02 AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Standing height 2.90 16 10 22.2 0.44 4.7e-02 AC074117.10 ADCY3 ADO CARD9 CCDC116 FUT2 HINT1 MIER1 MTMR3 PDE4A PDLIM4 PTRF RFT1 RP11-373D23.3 SLC22A5 ZBTB38
Seen doctor (GP) for nerves, anxiety, tension or depression 1.18 1 0 0.0 0.00 1.0e+00 MIER1
Hair/balding pattern: Pattern 4 1.17 1 1 2.2 0.00 1.0e+00 ZBTB38
Birth weight of first child 1.64 2 1 2.2 0.00 1.0e+00 TSPAN14 ZBTB38
Peak expiratory flow (PEF) 1.16 2 1 2.2 0.00 1.0e+00 AC010883.5 FUT2
Medication for cholesterol, blood pressure or diabetes 1.42 1 0 0.0 0.00 1.0e+00 FUT2
Gout (self-reported) 1.83 2 1 2.2 0.00 1.0e+00 AC074117.10 PPP1R14B
Hypothyroidism/myxoedema (self-reported) 3.43 8 3 6.7 -0.20 6.3e-01 BRD7 DCLRE1B GIGYF1 MTMR3 PPP1R14B PTRF RNASET2 ZMIZ1
Medication: Ventolin 100micrograms inhaler 2.69 5 2 4.4 0.51 3.0e-01 KIAA1109 LRRC32 NDFIP1 PNMT SMAD3
Birth weight 1.52 3 1 2.2 0.00 1.0e+00 FUT2 RFT1 RSPO3
Forced vital capacity (FVC), Best measure 1.20 5 4 8.9 0.35 5.7e-01 ADCY3 MTMR3 RFT1 STMN3 ZBTB38
Body fat percentage 1.50 4 3 6.7 0.60 4.0e-01 ADCY3 MST1 NFATC2IP ZBTB38
Leg fat percentage (right) 1.41 3 3 6.7 0.00 1.0e+00 ADCY3 MST1 NFATC2IP
Arm fat-free mass (right) 2.04 11 9 20.0 0.54 5.8e-02 AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38
Exposure to tobacco smoke outside home 1.63 1 0 0.0 0.00 1.0e+00 RP11-464F9.22
Comparative body size at age 10 3.07 4 2 4.4 0.52 4.8e-01 ADCY3 FUT2 NFATC2IP PLCL1
Wheeze or whistling in the chest in last year 2.21 4 3 6.7 0.49 4.1e-01 KIAA1109 LRRC32 PNMT SMAD3
Shortness of breath walking on level ground 1.39 1 0 0.0 0.00 1.0e+00 LRRC32
Qualifications: College or University degree 1.37 3 2 4.4 0.00 1.0e+00 MST1 NFATC2IP STMN3
Medication: Allopurinol 1.48 2 1 2.2 0.00 1.0e+00 AC074117.10 RP11-373D23.3
Medication: Seretide 50 evohaler 1.99 3 0 0.0 0.08 9.2e-01 PDLIM4 SLC22A5 SMAD3
Mean time to correctly identify matches 0.87 1 0 0.0 0.00 1.0e+00 ADCY3
Whole body fat mass 1.61 5 5 11.1 0.58 3.1e-01 ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Leg fat mass (right) 1.50 5 4 8.9 0.57 3.2e-01 ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Arm predicted mass (right) 2.05 11 9 20.0 0.43 1.4e-01 AC074117.10 CARD9 HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Pulse rate, automated reading 2.03 5 4 8.9 -0.23 7.1e-01 AC074117.10 C11orf30 GIGYF1 MST1 ZBTB38
Alcohol intake frequency. 1.63 4 3 6.7 -0.31 6.9e-01 AC074117.10 FUT2 MST1 NFATC2IP
Comparative height size at age 10 2.51 13 11 24.4 0.57 1.8e-02 AC010883.5 AC074117.10 ADCY3 CARD9 CCDC116 FUT2 HINT1 MTMR3 NFATC2IP PDLIM4 RFT1 SLC22A5 ZBTB38
Suffer from 'nerves' 1.11 1 1 2.2 0.00 1.0e+00 NFATC2IP
Overall health rating 1.11 1 1 2.2 0.00 1.0e+00 MST1
Hypertension (Self-reported) 1.31 4 3 6.7 0.20 7.5e-01 ADO FUT2 PDLIM4 SLC22A5
Illnesses of father: Heart disease 1.47 1 0 0.0 0.00 1.0e+00 SMAD3
Forced expiratory volume in 1-second (FEV1), predicted 1.88 5 2 4.4 0.90 1.4e-02 PDE4A PDLIM4 RFT1 SLC22A5 ZBTB38
Whole body fat-free mass 2.17 14 9 20.0 0.54 3.2e-02 AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Leg fat-free mass (right) 2.08 10 7 15.6 0.70 1.1e-02 AC074117.10 ADO HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38
Arm fat percentage (left) 1.61 4 3 6.7 0.59 4.1e-01 ADCY3 GALC MST1 NFATC2IP
Long-standing illness, disability or infirmity 1.77 1 0 0.0 0.00 1.0e+00 DCLRE1B
Diabetes diagnosed by doctor 1.88 2 2 4.4 0.00 1.0e+00 AC010883.5 AC074117.10
Qualifications: nursing, teaching 1.05 1 0 0.0 0.00 1.0e+00 MST1
Mouth/teeth dental problems: Mouth ulcers 2.33 4 2 4.4 0.03 9.7e-01 IL12B PNMT PPP5C TNFSF15
Medication for cholesterol 1.21 1 0 0.0 0.00 1.0e+00 FUT2
Asthma (self-reported) 5.60 11 7 15.6 0.18 5.3e-01 CUL2 HINT1 KIAA1109 LACC1 LRRC32 NCF4 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Osteoporosis (self-reported) 1.40 1 0 0.0 0.00 1.0e+00 PPP1R14B
Smoking status: Current 1.09 1 0 0.0 0.00 1.0e+00 STMN3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.01 2 0 0.0 0.00 1.0e+00 PNMT STMN3
Whole body water mass 2.15 14 9 20.0 0.54 3.2e-02 AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Leg predicted mass (right) 2.08 10 7 15.6 0.70 1.1e-02 AC074117.10 ADO HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38
Arm fat mass (left) 1.57 6 5 11.1 0.61 2.0e-01 ADCY3 GALC HINT1 MST1 NFATC2IP ZBTB38
Number of self-reported non-cancer illnesses 2.13 5 1 2.2 0.64 2.4e-01 AC074117.10 FUT2 LRRC32 SLC22A5 STMN3
Medication: Blood pressure 1.20 2 0 0.0 0.00 1.0e+00 PDLIM4 SLC22A5
High cholesterol (Self-reported) 1.92 2 2 4.4 0.00 1.0e+00 AC074117.10 FUT2
Medication: Bendroflumethiazide 1.57 2 1 2.2 0.00 1.0e+00 FUT2 PDLIM4
Medication: Atorvastatin 1.50 1 1 2.2 0.00 1.0e+00 AC074117.10
Basal metabolic rate 2.12 14 7 15.6 0.55 2.8e-02 AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Leg fat percentage (left) 1.48 3 3 6.7 0.00 1.0e+00 ADCY3 MST1 NFATC2IP
Arm fat-free mass (left) 2.07 12 10 22.2 0.46 9.6e-02 AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Number of operations (self-reported) 1.40 2 0 0.0 0.00 1.0e+00 MTMR3 PARK7
Irritability 1.07 2 0 0.0 0.00 1.0e+00 AC010883.5 ERAP2
Ever had prostate specific antigen (PSA) test 1.36 1 0 0.0 0.00 1.0e+00 ZBTB38
Fractured/broken bones in last 5 years 1.28 1 1 2.2 0.00 1.0e+00 RSPO3
Diastolic blood pressure, automated reading 1.54 7 5 11.1 0.12 7.9e-01 ADO DNAJC28 ERAP2 GIGYF1 MST1 PDLIM4 STMN3
Vascular/heart problems diagnosed by doctor 1.42 4 3 6.7 -0.11 8.3e-01 ADO FUT2 PDLIM4 SLC22A5
Cholesterol lowering medication 1.30 2 1 2.2 0.00 1.0e+00 AC074117.10 FUT2
Impedance of whole body 1.06 9 4 8.9 0.62 7.6e-02 AC010883.5 AC074117.10 ADCY3 HEATR3 HINT1 PLCL1 RP11-373D23.3 RP11-429P3.3 ZMIZ1
Leg fat mass (left) 1.51 5 4 8.9 0.57 3.2e-01 ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Arm predicted mass (left) 2.10 12 9 20.0 0.46 9.5e-02 AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 25 0.72 2.2
GTEx Adipose Visceral Omentum 15 0.74 2.2
GTEx Adrenal Gland 11 0.76 2.2
GTEx Artery Aorta 23 0.77 2.1
GTEx Artery Coronary 14 1.19 2.2
GTEx Artery Tibial 36 0.96 2.2
GTEx Brain Caudate basal ganglia 13 1.41 2.3
GTEx Brain Cerebellar Hemisphere 18 1.21 2.4
GTEx Brain Cerebellum 20 1.01 2.3
GTEx Brain Cortex 12 1.16 2.4
GTEx Brain Frontal Cortex BA9 7 0.76 2.2
GTEx Brain Hippocampus 5 0.95 2.2
GTEx Brain Hypothalamus 6 1.02 2.4
GTEx Brain Nucleus accumbens basal ganglia 12 1.39 2.3
GTEx Brain Putamen basal ganglia 7 1.12 2.4
GTEx Breast Mammary Tissue 17 0.86 2.1
GTEx Breast Mammary Tissue (Male) 11 0.92 2.2
GTEx Breast Mammary Tissue (Female) 11 0.67 2.1
GTEx Cells EBV-transformed lymphocytes 9 0.63 2.1
GTEx Cells Transformed fibroblasts 35 0.83 2.2
GTEx Colon Sigmoid 12 0.82 2.2
GTEx Colon Transverse 20 0.97 2.2
GTEx Esophagus Gastroesophageal Junction 21 1.45 2.3
GTEx Esophagus Mucosa 37 1.11 2.5
GTEx Esophagus Muscularis 29 0.90 2.2
GTEx Heart Atrial Appendage 15 0.95 2.4
GTEx Heart Left Ventricle 12 0.78 2.2
GTEx Liver 3 0.42 2.1
GTEx Lung 34 1.19 2.4
GTEx Muscle Skeletal 24 0.83 2.2
GTEx Nerve Tibial 42 0.97 2.2
GTEx Ovary 13 1.43 2.6
GTEx Pancreas 10 0.61 2.1
GTEx Pituitary 12 1.08 2.3
GTEx Prostate 10 1.20 2.5
GTEx Skin Not Sun Exposed Suprapubic 27 1.10 2.4
GTEx Skin Sun Exposed Lower leg 30 0.83 2.3
GTEx Small Intestine Terminal Ileum 4 0.88 2.1
GTEx Spleen 15 1.06 2.5
GTEx Stomach 15 1.03 2.3
GTEx Testis 27 0.86 2.2
GTEx Thyroid 33 0.83 2.2
GTEx Uterus 5 0.88 2.3
GTEx Vagina 8 1.26 2.4
GTEx Whole Blood 26 1.31 2.8
METSIM Adipose 44 0.96 2.2
NTR Blood 31 1.29 2.6
ROSMAP Brain Pre-frontal Cortex 31 0.71 2.0
YFS Blood 42 0.91 2.3
CommonMind Brain Pre-frontal Cortex 36 0.67 2.0
The Cancer Genome Atlas Bladder Urothelial Carcinoma 12 0.73 2.1
The Cancer Genome Atlas Breast Invasive Carcinoma 36 0.82 2.1
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 9 0.82 2.2
The Cancer Genome Atlas Colon Adenocarcinoma 17 0.82 2.3
The Cancer Genome Atlas Esophageal Carcinoma 3 0.44 1.9
The Cancer Genome Atlas Glioblastoma Multiforme 7 0.68 2.2
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 17 0.62 2.2
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 30 0.73 2.0
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 15 0.73 2.2
The Cancer Genome Atlas Brain Lower Grade Glioma 35 0.81 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 9 0.81 2.1
The Cancer Genome Atlas Lung Adenocarcinoma 28 0.95 2.4
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 22 0.88 2.2
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 11 0.69 2.1
The Cancer Genome Atlas Pancreatic Adenocarcinoma 11 0.66 2.2
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 10 0.76 2.2
The Cancer Genome Atlas Prostate Adenocarcinoma 33 0.71 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 8 1.15 2.7
The Cancer Genome Atlas Soft Tissue Sarcoma 5 0.47 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 6 1.12 2.3
The Cancer Genome Atlas Stomach Adenocarcinoma 13 0.77 2.2
The Cancer Genome Atlas Testicular Germ Cell Tumors 9 0.70 2.2
The Cancer Genome Atlas Thyroid Carcinoma 42 0.82 2.1
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 3 0.59 2.0